Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 11, 2026 · Filed Nov 13, 2026
The CFO of Aldeyra Therapeutics paid $6.5K out of pocket for Aldeyra Therapeutics shares. 1 other person at Aldeyra Therapeutics bought some too, in the same month. It was the first purchase in 8 months.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$6,500
Shares × reported transaction price
<$25K
+133.3%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 8 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 2 earlier confirmed purchases
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($848K)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-27. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
Closed at $0.6514 on Nov 11, 2026, 16% above its 52-week low and 88% below its high, after a 47% drop over the previous 30 trading days
52-week range $0.5603 (Oct 30, 2026) to $5.62 (Mar 2, 2026), 2% of the way up, from 251 adjusted closes. 30 trading days earlier: $1.23 on Sep 30, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider buying
Traded Nov 11 · filed 2 days later
An Aldeyra Therapeutics director paid $129K out of pocket for Aldeyra Therapeutics shares. 1 other person at Aldeyra Therapeutics bought some too, in the same month. It was the first purchase in 8 months.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
